Skip to main content

Protalix BioTherapeutics, Inc.

PLX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001006281

No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Protalix BioTherapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of PLX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders6661−5
Shares8.98M9.17M+191.1K (+2.1%)
Value$17.9M$15.2M−$2.69M (−15.0%)

New holders (9)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to PLX in Q3 2023
InstitutionSharesValue% of portfolio
Gsa Capital Partners LLP496,781$825.0K0.07%
Allspring Global Investments Holdings, LLC137,906$228.9K0.00%
State of Wyoming41,268$68.5K0.01%
HSBC Holdings PLC40,066$64.5K0.00%
SG Americas Securities, LLC30,008$50.0K0.00%
Citadel Advisors LLC25,614$42.5K0.00%
Russell Investments Group, Ltd.2,764$4.59K0.00%
Geneos Wealth Management Inc.2,000$3.32K0.00%
Highlander Capital Management, LLC610$1.00K0.00%

Sold out (14)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of PLX in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Marshall Wace, LLP562,139$1.12M
Jane Street Group, LLC276,082$552.2K
EAM Investors, LLC165,631$331.3K
Natixis132,000$264.0K
Verition Fund Management LLC54,474$108.9K
MetLife Investment Management32,363$64.7K
IHT Wealth Management, LLC28,800$57.6K
Millennium Management LLC21,232$42.5K
Wolverine Trading, LLC17,208$37.3K
Susquehanna International Group, LLP15,864$31.7K
Two Sigma Securities, LLC15,276$30.6K
Metropolitan Life Insurance Co3,354$6.71K
WealthPLAN Partners, LLC575$1.15K
GWM Advisors LLC536$1.07K